A CLINICAL EVALUATION OF THE SAFETY OF BACLOFEN ER CAPSULES (GRS) WHEN ADMINISTERED ONCE DAILY TO SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS (MS): AN OPEN LABEL, LONG TERM, SAFETY TRIAL

Trial Profile

A CLINICAL EVALUATION OF THE SAFETY OF BACLOFEN ER CAPSULES (GRS) WHEN ADMINISTERED ONCE DAILY TO SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS (MS): AN OPEN LABEL, LONG TERM, SAFETY TRIAL

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Baclofen (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Adverse reactions
  • Sponsors Sun Pharma Advanced Research Company
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Jul 2017.
    • 24 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2017.
    • 24 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top